Emblaveo Receives EC Approval For Patients with Multidrug-resistant Infections

Pfizer Inc., a biopharmaceutical firm, reported that Emblaveo (aztreonam-avibactam) has received marketing approval from the European Commission (EC) for the treatment of adult patients with pyelonephritis, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI). Adult patients with limited treatment options can also use it to treat infections caused by aerobic Gram-negative organisms. 

“For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study. “The approval of Emblaveo is welcome news for the infectious disease community and provides new hope to critically ill patients affected by antimicrobial resistance.”

Antimicrobial resistance (AMR) - when microbes, infections, growths, and parasites change and track down ways of opposing the impacts of antimicrobial medications - is perceived as one of the greatest dangers to global health. Minor infections could become life-threatening if AMR continues to rise unchecked, and numerous routine medical procedures like cesarean sections and hip replacements could become too risky to perform.

“The European Medicines Agency’s accelerated review of Emblaveo reflects the urgent need for new treatments to address the threat of antimicrobial resistance,” said Alexandre de Germay, chief international commercial officer, executive vice president, Pfizer. “With this approval, Pfizer is proud to take another step forward in its commitment to developing and bringing breakthrough health solutions to patients impacted by serious infectious diseases around the world.”